Healthcare in a Changing Climate 2025

72. Gupta, A., Dialynas, C., McLaughlin, M. & Richie, J. (2024). Advancing Innovative Treatments for Mental Health Care. Milken Institute. https://milkeninstitute.org/sites/default/files/2024-04/AdvancingInnovativeTreatmentsMentalHealthCare.pdf. 73. Gupta, A., Dialynas, C., McLaughlin, M. & Richie, J. (2024). Advancing Innovative Treatments for Mental Health Care. Milken Institute. https://milkeninstitute.org/sites/default/files/2024-04/AdvancingInnovativeTreatmentsMentalHealthCare.pdf. 74. Gupta, A., Dialynas, C., McLaughlin, M. & Richie, J. (2024). Advancing Innovative Treatments for Mental Health Care. Milken Institute. https://milkeninstitute.org/sites/default/files/2024-04/AdvancingInnovativeTreatmentsMentalHealthCare.pdf. 75. Gupta, A., Dialynas, C., McLaughlin, M. & Richie, J. (2024). Advancing Innovative Treatments for Mental Health Care. Milken Institute. https://milkeninstitute.org/sites/default/files/2024-04/AdvancingInnovativeTreatmentsMentalHealthCare.pdf. 76. Mao, W., Cooke, R., Silimperi, D., Urli Hodges, E., Ortiz, E. & Udayakumar, K. (2023). Scaling malaria interventions: bottlenecks to malaria elimination. BMJ Global Health, vol. 8, no. 11. https://pmc.ncbi.nlm.nih.gov/articles/ PMC10649629/#R6. 77. Orphanet. (2024). About Orphan Drugs. https://www.orpha.net/en/other-information/about-orphan- drugs?stapage=countries. 78. Benesty, J., Serazin, E., Short, H. & Zheng, S. (2024). Addressing Challenges at the Intersection of Climate and Health. Boston Consulting Group (BCG). https://www.bcg.com/publications/2024/addressing-challenges-intersection-of-climate- and-health. 79. Pfizer. (2020). Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA- based Vaccine Candidate Against SARS-CoV-2. https://www.pfizer.com/news/press-release/press-release-detail/pfizer- and-biontech-announce-agreement-us-government-600. 80. Sagonowsky, E. (2020). After nearly $1B in research funding, Moderna takes $1.5B coronavirus vaccine order from U.S. Fierce Pharma. https://www.fiercepharma.com/pharma/after-nearly-1b-research-funding-moderna-takes-1-5b- coronavirus-vaccine-order-from-u-s. 81. Gavi, the Vaccine Alliance. (2024). https://www.gavi.org/. 82. Gavi, the Vaccine Alliance. (2024). https://www.gavi.org/. 83. Mao, W., Cooke, R., Silimperi, D., Urli Hodges, E., Ortiz, E. & Udayakumar, K. (2023). Scaling malaria interventions: bottlenecks to malaria elimination. BMJ Global Health, vol. 8, no. 11. https://pmc.ncbi.nlm.nih.gov/articles/ PMC10649629/#R10. 84. World Health Organization (WHO), WHO Regulation and Prequalification Department. (2023). PQT Unit. https://cdn. who.int/media/docs/default-source/health-products-policy-and-standards/19_prequalification-processes-and-activities- overview---lawrence-nzumbu.pdf. 85. Mao, W., Cooke, R., Silimperi, D., Urli Hodges, E., Ortiz, E. & Udayakumar, K. (2023). Scaling malaria interventions: bottlenecks to malaria elimination. BMJ Global Health, vol. 8, no. 11. https://pmc.ncbi.nlm.nih.gov/articles/ PMC10649629/#R10. 86. Gupta, A., Dialynas, C., McLaughlin, M. & Richie, J. (2024). Advancing Innovative Treatments for Mental Health Care. Milken Institute. https://milkeninstitute.org/sites/default/files/2024-04/AdvancingInnovativeTreatmentsMentalHealthCare.pdf. 87. Gupta, A., Dialynas, C., McLaughlin, M. & Richie, J. (2024). Advancing Innovative Treatments for Mental Health Care. Milken Institute. https://milkeninstitute.org/sites/default/files/2024-04/AdvancingInnovativeTreatmentsMentalHealthCare.pdf. 88. Parums, D.V. (2021). Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine and the Real-World Implications for Public Health Policy. Medical Science Monitor, PubMed Central, vol. 27. https://pmc.ncbi.nlm.nih.gov/articles/PMC8434768/. 89. Kuter, B.J., Offit, P .A. & Poland, G.A. (2021). The development of COVID-19 vaccines in the United States: Why and how so fast? Vaccine, PubMed Central, vol. 39, no. 18, pp. 2491-2495. https://pmc.ncbi.nlm.nih.gov/articles/PMC7997594/. 90. Giattino, C., Ritchie, H., Ortiz-Ospina, E., Hasell, J., Rodés-Guirao, L. & Roser, M. (2024). Excess mortality during the Coronavirus pandemic (COVID-19). OurWorldInData.org. https://ourworldindata.org/excess-mortality-covid?country=IND ~USA~GBR~CAN~DEU~FRA. 91. European Union, EUR-Lex. (2006). COMMISSION STAFF WORKING DOCUMENT EVALUATION Joint evaluation of Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. https://eur-lex.europa.eu/legal-content/EN/ TXT/?uri=CELEX%3A52020SC0163. 92. Parrish, M. & Waddick, K. (2023). Pharma’s rare disease rush. PharmaVoice. https://www.pharmavoice.com/news/ pharmas-rare-disease-rush/690686/. 93. Fortune Business Insights. (2024). Orphan Drugs Market Size, Share & Industry Analysis, By Therapy Area (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Infectious Diseases and Others), By Drug Type (Biologics and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others) and Regional Forecast, 2024-2032. https://www.fortunebusinessinsights.com/industry-reports/ orphan-drugs-market-100088. 94. Visiongain Reports Ltd. (2024). Rare Diseases market is projected to grow at a CAGR of 8.8% by 2034: Visiongain. https://www.globenewswire.com/news-release/2024/06/06/2894923/0/en/Rare-Diseases-market-is-projected-to-grow- at-a-CAGR-of-8-8-by-2034-Visiongain.html. Healthcare in a Changing Climate: Investing in Resilient Solutions 44